NCT05364905已完成不适用
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma: A Retrospective Study
ARCAGY/ GINECO GROUP30 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2022年5月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 30
- 主要终点
- Clinical, biological and treatment characteristics
研究概览
简要总结
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult women ≥ 18 years at index date.
- •Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
- •Index date should represent at least the first* or second line** chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December
- •do not express refusal to her personal data processing or did not express her refusal for deceased patients.
排除标准
- •No clinical records for tumor imaging or administration of anti-cancer therapy.
- •Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
- •Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
- •Patient did not receive chemotherapy systemic treatment.
- •Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.
研究组 & 干预措施
Cohort 1
Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019
干预措施: Chemotherapy (Drug)
Cohort 2
Patients in second line treatment (after one prior systemic chemotherapy) in 2019
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Clinical, biological and treatment characteristics
时间窗: up to 3 years
Description of the data
次要结局
- Overall Survival (OS)(through study completion, an average of 1 year)
- Progession Free Survival real world (rwPFS)(through study completion, an average of 1 year)
研究者
研究点 (30)
Loading locations...
相似试验
已完成
不适用
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell CentersSickle Cell DiseaseNCT05833022Novartis Pharmaceuticals297
已完成
不适用
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast CancerBreast CancerNCT04987931Pfizer84
终止
不适用
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesBreast CancerNCT04396626Pfizer975
已完成
不适用
Multicenter Retrospective Observational Study of Acute Myocarditis in KoreaMyocarditis AcuteNCT05933902Samsung Medical Center841
已完成
不适用
Use of Canagliflozin in Conjunction With Insulin in a Real-world SettingType 2 Diabetes MellitusNCT02681497Lawson Health Research Institute269